

Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2026	
Wynn Hotel & Casino, Las Vegas, Nevada	
November 13-14, 2026	
Mouton 2 Conference Room	
Day 1	Friday, November 13, 2026
7:30 AM	Breakfast, Registration and Exhibits
8:20 AM	Welcome Announcements Tanios S. Bekaii-Saab, M.D.
Liver Session I: Challenges and Controversies in Advanced HCC Moderator: G. Dan Duda, D.M.D., Ph.D., FAIMBE, FAAAS	
8:30 AM	Debate: Anti-angiogenic and Checkpoints Are the Preferred Options for Advanced HCC Ghassan K. Abou-Alfa, M.D., J.D., M.B.A., Ph.D. (hc)
8:40 AM	Debate: STRIDE Regimen Would Be the Preferred Option for Advanced HCC Richard S. Finn, M.D.
8:50 AM	Debate: Sustained Doublet Checkpoint Inhibitors Is the Way Forward For Advanced HCC Anthony B. El-Khoueiry, M.D.
9:00 AM	Interactive Q&A Session Presenters
Liver Session II: Managing HCC Challenges Moderator: Amit K. Mathur, M.D.	
9:15 AM	Expanding Indications for Surgical Resection in Hepatocellular Carcinoma: What is the Evidence? Adam Yopp, M.D.
9:35 AM	Modern HCC Transplantation Indications/Criteria: Primer for Non-Transplant Surgeons Christopher J. Sonnenday, M.D., M.H.S.
9:55 AM	Fibrolamellar HCC: Surgical Management of Localized/Metastatic Disease Ching-Wei D. Tzeng, M.D.
10:10 AM	Systemic Therapies for Fibrolamellar Carcinoma (FLC/FL-HCC) John Gordan, M.D., Ph.D.
10:25 AM	Interactive Q&A Session Presenters
10:40 AM	AM Break and Exhibits
Liver Session III: Multidisciplinary Tumor Board	

Moderator: Channa R. Jayasekera, M.D. (10:45 AM - 11:15 AM), Daniel H. Ahn, D.O. (11:15 AM - 11:45AM)	
11:00 AM	Treatment Strategies for "Early-Stage" HCC Panelists: Amit K. Mathur, M.D., Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Ching-Wei D. Tzeng, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., Richard G. Frimpong, M.D., John Gordan, M.D., Ph.D. and Hani M. Babiker, M.D.
11:30 AM	Treatment Strategies for "Advanced" HCC Panelists: Amit K. Mathur, M.D., Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Ching-Wei D. Tzeng, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., Richard G. Frimpong, M.D., John Gordan, M.D., Ph.D. and Hani M. Babiker, M.D.
12:00 PM	Lunch & Exhibits
12:00 PM	Optional Product Theater 1: Exelixis (no CME credit) Location: Montrachet
State of the Art HPB Lecture Moderator: Mark J. Truty, M.D., M.S.	
1:00 PM	Endoscopic Palliative and Therapeutic Bypass Procedures in HPB Oncology: What is Now Possible Ryan J. Law, D.O.
1:30 PM	Interactive Q&A Session Presenters
Biliary Session I: Precision Oncology for Advanced Disease Moderator: Mitesh J. Borad, M.D.	
1:40 PM	Precision Medicine Advances in HCC – The Next Frontier? Nguyen H. Tran, M.D.
1:55 PM	Choosing Between HER2 Targeted Therapies in Biliary Tract Malignancies Milind M. Javle, M.D.
2:05 PM	IDH1/IDH2 and Emerging Opportunities in Biliary Tract Cancers Caitlin B. Conboy, M.D., Ph.D.
2:15 PM	Applications of Liquid Biopsy Technologies in the Management of Hepatobiliary Cancers Umair Majeed, M.B.B.S., M.D.
2:25 PM	FGFR Inhibitors – Where Have We Been and Where Are We Going?

	Daniel H. Ahn, D.O.
2:35 PM	Interactive Q&A Session Presenters
2:50 PM	PM Break and Exhibits
Biliary Session II: Challenges and Controversies in Localized Disease Moderator: Dominic E. Sanford, M.D.,	
3:10 PM	Incidental Gallbladder Cancer: Now What? Mark J. Truty, M.D., M.S.
3:25 PM	Transplant in Cholangiocarcinoma – Current and Evolving Indications Channa R. Jayasekera, M.D.
3:40 PM	National Strategic Approach to Managing the Gallbladder Cancer Epidemic in Chile Jorge Gallardo, M.D.
3:55 PM	Is Adjuvant Therapy Appropriate for all Resected BTC Patients? Midhun Malla, M.D.
4:10 PM	Interactive Q&A Session Presenters
Biliary Session III: Multidisciplinary Tumor Board Moderator: Daniel H. Ahn, D.O.	
4:25 PM	Localized Intrahepatic CCA Panelists: Dominic E. Sanford, M.D., Channa R. Jayasekera, M.D., Jorge Gallardo, M.D., Midhun Malla, M.D., Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Amit K. Mathur, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., Nitin N. Katariya, M.D., and Richard G. Frimpong, M.D.
4:45 PM	Neoadjuvant Therapy for Intrahepatic CCA Panelists: Dominic E. Sanford, M.D., Channa R. Jayasekera, M.D., Jorge Gallardo, M.D., Midhun Malla, M.D., Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Amit K. Mathur, M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., Nitin N. Katariya, M.D., and Richard G. Frimpong, M.D.
5:05 PM	Management of Peri-Hilar CCA Panelists: Dominic E. Sanford, M.D., Channa R. Jayasekera, M.D., Jorge Gallardo, M.D., Midhun Malla, M.D., Adam Yopp, M.D., Christopher J. Sonnenday, M.D., M.H.S., Amit K. Mathur,

	M.D., Daniel A. Adamo, M.D., Yasamin Sharifzadeh-Moghaddam, M.D., Nitin N. Katariya, M.D., and Richard G. Frimpong, M.D.
5:25 PM	Interactive Q&A Session Presenters
5:35 PM	Closing Remarks and Adjourn

Day 2	Saturday, November 14, 2026
7:15 AM	Breakfast & Exhibits
7:15 AM	Optional Product Theater: Company 2 (no CME credit) Location: Montrachet
8:20 AM	Welcome Announcements
Pancreas Session I: Precision Oncology in the Treatment of Pancreatic Adenocarcinoma Moderator: Tanios S. Bekaii-Saab, M.D.	
8:30 AM	"KRA"cking the RAS Code in PDAC Nilofer S. Azad, M.D., F.A.S.C.O.
8:45 AM	KRAS WT PDAC: Targets Galore Bassel F. El-Rayes, M.D.
9:00 AM	Other Emerging Targets in PDAC Ben George, M.B.B.S., M.D.
Pancreas Session II: Reimagining the Standard in Localized Pancreatic Cancer Moderator: Ryan M. Carr, M.D., Ph.D.	
9:20 AM	Next-Generation Trial Design in the Perioperative Management of Pancreatic Cancer Eileen M. O'Reilly, M.D.
9:40 AM	The Role of PET in Staging and Response in Pancreatic Adenocarcinoma Mark J. Truty, M.D., M.S.
10:00 AM	Interactive Q&A Session Presenters
10:15 AM	AM Break and Exhibits
Pancreas Session III: Advances in Neuroendocrine and Other Pancreatic Malignancies	

Moderator: Thor R. Halfdanarson, M.D.	
10:35 AM	Radionuclide Therapy in Neuroendocrine Tumors: Current Landscape and Future Directions Cliff Shin, M.D., Ph.D.
10:50 AM	Surgical Management of Functioning and Non-Functioning Pancreatic Neuroendocrine Tumors Alexandra Gangi, M.D.
11:10 AM	Neoadjuvant Therapy for PNET: CAP/TEM and Beyond Thor R. Halfdanarson, M.D.
11:30 AM	De Novo PDAC vs Invasive-IPMN: Is There a Real Difference? Katherine Poruk, M.D.
11:50 AM	Interactive Q&A Session Presenters
Pancreas Session IV: Multidisciplinary Tumor Board Moderator: Katherin Poruk, M.D., and Thor R. Halfdanarson, M.D.	
12:05 PM	Localized PNET Panelists: Eileen M. O'Reilly, M.D., Bassel F. El-Reyes, M.D., Nilofer S. Azad, M.D., F.A.S.C.O., Ben George, M.B.B.S., M.D., Cliff Shin, M.D., Ph.D., Alexandra Gangi, M.D., Mark J. Truty, M.D., M.S., and Daniel Adamo, M.D.
12:25 PM	High Risk Non-Metastatic PDAC Panelists: Eileen M. O'Reilly, M.D., Bassel F. El-Reyes, M.D., Nilofer S. Azad, M.D., F.A.S.C.O., Ben George, M.B.B.S., M.D., Cliff Shin, M.D., Ph.D., Alexandra Gangi, M.D., Mark J. Truty, M.D., M.S., and Daniel Adamo, M.D.
12:45 PM	Recurrent/Metastatic PDAC/PNET Panelists: Eileen M. O'Reilly, M.D., Bassel F. El-Reyes, M.D., Nilofer S. Azad, M.D., F.A.S.C.O., Ben George, M.B.B.S., M.D., Cliff Shin, M.D., Ph.D., Alexandra Gangi, M.D., Mark J. Truty, M.D., M.S., and Daniel Adamo, M.D.
1:05 PM	Interactive Q&A Session Presenters
1:20 PM	Closing Remarks and Adjourn

